Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation
Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A
Record ID 32010000250
English
Authors' recommendations:
Study found that higher doses of intensity-modulated radiotherapy (IMRT), up to 81 Gy, can improve biochemical survival for patients with localised prostate cancer. Data also suggest that toxicity can be reduced by increasing conformality of treatment, particularly with regard to gastrointestinal (GI) toxicity, which can be more easily achieved with IMRT than three-dimensional conformal radiotherapy (3DCRT). Whether differences in GI toxicity between IMRT and 3DCRT are sufficient for IMRT to be cost-effective is uncertain, depending on the difference in incidence of GI toxicity, its duration and the cost difference between IMRT and 3DCRT
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1788
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Prostatic Neoplasms
- Radiotherapy Dosage
- Radiotherapy, Intensity-Modulated
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2010 Queen’s Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.